Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170193 · ClinicalTrials.gov registry record · Phase 1
AMG 529 First in Human Study
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03170193 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 48 participants.
The verdict
NCT03170193, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
A study to assess the safety and tolerability of AMG 529 following single, ascending doses administered subcutaneously (SC) or intravenously (IV) in healthy adults.
Interventions
- DRUG Placebo
- DRUG AMG 529
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170193
The ClinicalTrials.gov registry entry for NCT03170193 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03170193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170193 about?
NCT03170193 is a clinical study titled "AMG 529 First in Human Study". A study to assess the safety and tolerability of AMG 529 following single, ascending doses administered subcutaneously (SC) or intravenously (IV) in healthy adults.
What is the current status of trial NCT03170193?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-05-15. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT03170193?
The interventions under investigation include: Placebo (DRUG), AMG 529 (DRUG).
Who is sponsoring clinical trial NCT03170193?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.